Atrial fibrillation associated with higher death risk in motor vehicle accident victims

June 10, 2016

Nice, France - 10 June 2016: A study in nearly three million motor vehicle accident victims has found that atrial fibrillation is associated with a higher risk of death. The research was presented today at CARDIOSTIM - EHRA EUROPACE 2016 by Dr Abhishek Deshmukh, a cardiologist at the Mayo Clinic in Rochester, Minnesota, US.1

"Atrial fibrillation is the most common heart rhythm disorder and incidence is rising," said Dr Deshmukh. "Many of these patients are on anticoagulants to lower their stroke risk but these drugs increase the chance of bleeding."

He continued: "There is limited information about the impact of atrial fibrillation on daily activities such as driving. This is the first study to investigate the effect of atrial fibrillation on death and length of hospital stay after a motor vehicle accident."

The study used the Nationwide Inpatient Sample, the largest hospitalisation database in the US. It contains information on around 20% of hospitalisations in the country and can be used to calculate national estimates. The study included nearly 2 980 000 drivers, passengers and bystanders admitted to hospital due to a motor vehicle accident between 2003 and 2012. Of these, 79 687 (2.6%) had atrial fibrillation.

The investigators compared the chance of dying in hospital, length of hospital stay, chance of blood transfusion, and cost of hospitalisation between patients with and without atrial fibrillation.

Death in hospital occurred in 2.6% of those who had been in a motor vehicle accident and did not have atrial fibrillation, and 7.6% of patients who had been in a motor vehicle accident and had atrial fibrillation.

When the investigators looked at the mortality data for those who had been in a motor vehicle accident, they found that patients with atrial fibrillation had a 1.5 times higher chance of dying in hospital than those without atrial fibrillation, after adjusting for age, gender, comorbidities, and injury severity scores.

Dr Deshmukh said: "Atrial fibrillation is associated with higher mortality, length of stay and cost when patients are hospitalised for bypass surgery, hip replacement, or heart failure. Our research shows that atrial fibrillation is also associated with worse outcomes in patients involved in motor vehicle accidents."

The average length of hospital stay after a motor vehicle accident was nine days in those with atrial fibrillation and six days in those without. The average cost of hospital stay after a motor vehicle accident was $19 615 in those without atrial fibrillation, rising to $28 217 when patients also had atrial fibrillation.

After adjusting for factors that could influence the associations, the investigators found that atrial fibrillation was independently associated with a mean 2.4 day longer length of hospital stay and a mean $7 406 greater cost of hospitalisation after a motor vehicle accident.

The researchers also looked at the atrial fibrillation patients who had been hospitalised due to a motor vehicle accident according to their CHADS2 score, which is a measure of stroke risk that gives points to comorbidities such as heart failure, hypertension and diabetes. Patients with a score of 2 or more comorbidities had a higher chance of dying in hospital, bleeding, or requiring a blood transfusion.

Dr Deshmukh said: "We don't know which patients with atrial fibrillation were taking anticoagulants because this information was not in the database. It is likely that patients with a CHADS2 score of 2 or more are taking this medication. If they get into a car wreck then these drugs could have an impact, particularly the new anticoagulants that don't have a well tested reversal agent."

He concluded: "We should not jump the gun and advise patients with atrial fibrillation to stop driving. This was a retrospective observational study and needs to be confirmed by further research. Only then will we be in a position to give practical advice to patients with a higher risk."
References and notes:

1Dr Deshmukh will present the abstract 'Impact of atrial fibrillation on patients with motor vehicle accidents' during Poster Session 216: Ablation which takes place on 10 June from 14:00 to 17:30 in the Poster Area.


CARDIOSTIM - EHRA EUROPACE is an established, international conference attracting key opinion leaders, well-recognised scientists, physicians, allied professionals and industry.

About the European Heart Rhythm Association

The European Heart Rhythm Association (EHRA) is a registered branch of the European Society of Cardiology (ESC). Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reducing sudden cardiac death. EHRA promotes science and education in the field of cardiac arrhythmias with a special focus on atrial fibrillation (AF). Besides patient engagement programmes, EHRA organises scientific and educational events for physicians and allied professionals. In cooperation with other associations and societies EHRA promotes the quality of care for patients with AF with the publication of international consensus documents.

About the European Society of Cardiology

The European Society of Cardiology (ESC) represents more than 95 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

Information for journalists attending CARDIOSTIM - EHRA EUROPACE 2016

CARDIOSTIM - EHRA EUROPACE 2016 takes place 8 to 11 June at the Nice Acropolis Convention Centre. The full scientific programme is available here

To register please contact Catherine Rouillé on +33 6 73 62 57 61 or

European Society of Cardiology

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to